VANDA方案序贯贝林妥欧单抗使首次复发的费城染色体阴性B前体急性淋巴细胞白血病患者获得良好结局
研究评估贝林妥欧单抗联合强化化疗VANDA方案治疗复发/难治性B前体急性淋巴细胞白血病的活性。17例患者中14例(82%)达完全缓解,11例(65%)接受移植;全队列1年无白血病生存率58.8%,移植患者为90.9%。初步数据提示该挽救方案在合适患者中可获得很高的完全缓解率和造血干细胞移植率。
要点
- 贝林妥欧单抗联合VANDA方案治疗17例复发/难治性B前体急性淋巴细胞白血病。
- 完全缓解率82%(14/17),65%(11/17)后续接受造血干细胞移植。
- 全队列1年无白血病生存率58.8%,移植患者为90.9%。
核心结论
- 初步数据提示VANDA-贝林妥欧单抗挽救方案在合适患者中可获得很高的完全缓解率和造血干细胞移植率。
研究设计与样本
- 研究纳入17例复发/难治性B前体急性淋巴细胞白血病患者,接受贝林妥欧单抗与VANDA方案(依托泊苷、阿糖胞苷、米托蒽醌、地塞米松和门冬酰胺酶)联合治疗。
主要发现
- 17例患者中14例(82%)达到完全缓解。
- 17例患者中11例(65%)接受移植。
- 全队列1年无白血病生存率为58.8%,移植患者为90.9%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文称这些为初步数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adults with relapsed or refractory B-precursor acute lymphoblastic leukaemia (R/R BCP-ALL) have very poor outcome. Blinatumomab as single agent has shown activity in R/R BCP-ALL. We aimed to assess the activity of blinatumomab in concomitant association with intensive chemotherapy. Seventeen patients with R/R BCP-ALL were treated with combination of blinatumomab and VANDA (etoposide, cytarabine, mitoxantrone, dexamethasone and asparaginase) regimen. Complete remission (CR) was achieved in 14/17 patient (82%) and 11/17 (65%) were transplanted. One-year leukaemia-free survival was 58.8% for the whole cohort and 90.9% for transplanted patients. These preliminary data suggest that the VANDA-blinatumomab salvage regimen leads to a very high rate of CR and HSCT in suitable patients.
引用
- Heraudet L, Galtier J, Favre S, et al. VANDA regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome-negative B-precursor acute lymphoblastic leukaemia in first relapse. Br J Haematol. 2022. PMID: 35524489. doi:10.1111/bjh.18218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。